Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Events—Application to Clinical Trials in Chronic Heart Failure-Reference-Cited by-同舟云学术

Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Events—Application to Clinical Trials in Chronic Heart Failure

Published:2021-08-04 Issue: Volume: Page:1-12
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Fritsch Arno¹,Schlömer Patrick²,Mendolia Franco¹,Mütze Tobias³^ORCID,Jahn-Eimermacher Antje⁴,

Affiliation:

1. Bayer AG, Pharmaceuticals, Wuppertal, Germany

2. Bayer AG, Pharmaceuticals, Berlin, Germany

3. Novartis Pharma AG, Basel, Switzerland

4. Department of Mathematics and Natural Sciences, Darmstadt University of Applied Sciences, Darmstadt, Germany

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2021.1945488

Reference41 articles.

1. Does Cox analysis of a randomized survival study yield a causal treatment effect?

2. Cox's Regression Model for Counting Processes: A Large Sample Study

3. Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?

4. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic;Statistics in Biopharmaceutical Research;2024-08-21

2. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial;European Journal of Heart Failure;2024-05-14

3. Simulation‐based sample size calculations of marginal proportional means models for recurrent events with competing risks;Pharmaceutical Statistics;2024-03-20

4. Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation;Statistics in Biopharmaceutical Research;2023-12-12

5. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials;NEJM Evidence;2023-10-24